Research progress on the mechanism of β-adrenergic receptor signaling pathway regulating myocardial fibrosis in heart failure
WANG Xinting1 LU Cheng2 SHI Tianyun1 ZHONG Yihang1 LIU Yongming1▲
1. Department of Cardiovascular Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2. Department of Cardiovascular Medicine, the Seventh People′s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Abstract：Myocardial fibrosis is closely related to heart failure. The development of heart failure is accompanied by pathological changes of myocardial fibrosis. Myocardial fibrosis refers to the excessive accumulation of collagen in myocardial tissue structure, which is the main manifestation of adverse myocardial remodeling. Myocardial remodeling can reduce tissue compliance, damage cardiac function, promote the occurrence of arrhythmia and accelerate the progress of heart failure. Abnormal β-adrenergic receptor (βAR) signaling pathway is an important feature of heart failure. βAR plays a fundamental role in the physiological regulation of myocardium. Over activation of βAR system can promote the fibrosis process of heart failure, induce fibroblast proliferation, collagen secretion, migration and transform into myofibroblast phenotype. In this paper, the role of βAR signaling pathway in myocardial fibrosis of heart failure and the relationship between β1AR, β2AR, β3AR and myocardial fibrosis were discussed, so as to provide the development of potential therapeutic strategies for effective targeting at the pathological mechanism of disease progression.
Webber M，Jackson SP，Moon JC，et al.Myocardial Fibrosis in Heart Failure：Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials[J].Cardiol Ther，2020，9（2）：363-376.
[5]
López B，González A，Ravassa S，et al.Circulating Biomarkers of Myocardial Fibrosis：The Need for a Reappraisal[J].J Am Coll Cardiol，2015，65（22）：2449-2456.
[6]
Zhang Y，Wang WE，Zhang X，et al.Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart[J].Circ Res，2019，124（12）：1760-1777.
[7]
Ito A，Ohnuki Y，Suita K，et al.Role of β-adrenergic signaling in masseter muscle[J].PLoS One，2019，14（4）：e0215539.
[8]
Gyongyosi M，Winkler J，Ramos I，et al.Myocardial fibrosis：biomedical research from bench to bedside[J].Eur J Heart Fail，2017，19（2）：177-191.
[9]
Ravassa S，González A，Bayés-Genís A，et al.Myocardial interstitial fibrosis in the era of precision medicine.Biomarker-based phenotyping for a personalized treatment[J].Rev Esp Cardiol，2020，73（3）：248-254.
Eijgenraam TR，Silljé HHW，De Boer RA.Current understanding of fibrosis in genetic cardiomyopathies[J].Trends Cardiovasc Med，2020，30（6）：353-361.
[12]
González A，Schelbert EB，Díez J，et al.Myocardial Interstitial Fibrosis in Heart Failure：Biological and Translational Perspectives[J].J Am Coll Cardiol，2018，71（15）：1696-1706.
[13]
Bing R，Dweck MR.Myocardial fibrosis：why image，how to image and clinical implications[J].Heart，2019，105（23）：1832-1840.
[14]
Kiriazis H，Wang K，Xu Q，et al.Knockout of beta（1）- and beta （2）-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis[J].Br J Pharmacol，2008，153（4）：684-692.
[15]
Xiao H，Li H，Wang JJ，et al.IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult[J].Eur Heart J，2018，39（1）：60-69.
[16]
Dang S，Zhang ZY，Li KL，et al.Blockade of β-adrenergic signaling suppresses inflammasome and alleviates cardiac fibrosis[J].Ann Transl Med，2020，8（4）：127.
[17]
Hu H，Jiang M，Cao Y，et al.HuR regulates phospholamban expression in isoproterenol-induced cardiac remodeling[J].Cardiovasc Res，2020，116（5）：944-955.
[18]
Govindappa PK，Patil M，Garikipati VNS，et al.Targeting exosome-associated human antigen R attenuates fibrosis and inflammation in diabetic heart[J].FASEB J，2020，34（2）：2238-2251.
[19]
Green LC，Anthony SR，Slone S，et al.Identification of Human Antigen R （HuR） as a central mediator of cardiac fibrosis[J].FASEB J，2018，32：839.5.
[20]
Du Y，Zhang S，Yu H，et al.Autoantibodies Against β1-Adrenoceptor Exaggerated Ventricular Remodeling by Inhibiting CTRP9 Expression[J].J Am Heart Assoc，2019，8（4）：e010475.
[21]
Lv T，Du Y，Cao N，et al.Proliferation in cardiac fibroblasts induced by β1-adrenoceptor autoantibody and the underlying mechanisms[J].Sci Rep，2016，6：32 430.
[22]
Lim TB，Aliwarga E，Luu TDA，et al.Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy[J].Cardiovasc Res，2019，115（14）：1998-2007.
Li J，Philip JL，Xu X，et al.β-Arrestins regulate human cardiac fibroblast transformation and collagen synthesis in adverse ventricular remodeling[J].J Mol Cell Cardiol，2014，76：73-83.
[25]
Philip JL，Razzaque MA，Han M，et al.Regulation of mitochondrial oxidative stress by β-arrestins in cultured human cardiac fibroblasts[J].Dis Model Mech，2015，8（12）：1579-1589.
[26]
Kiriazis H，Wang K，Xu Q，et al.Knockout of b1- and b2-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis[J].Br J Pharmacol，2008，153：684-692.
[27]
Xu Q，Dalic A，Fang L，et al.Myocardial oxidative stress contributes to transgenic β2-adrenoceptor activation-induced cardiomyopathy and heart failure[J].Br J Pharmacol，2011，162（5）：1012-1028.
京公网安备 11010502046607号